ICU Medical, Inc.

Valuation Analysis

About the Company

ICU Medical, Inc. en bref

ICU Medical, Inc. (ICUI) is currently trading at 122,37 € with a market capitalization of 3,1 Md €. The trailing P/E ratio stands at 75.06x, with a forward P/E of 15.09x. The 52-week range spans from 93,28 € to 139,74 €; the current price is 12.4% below the yearly high. Year-over-year revenue growth stands at -12.3%. The net profit margin stands at 2.15%.

💰 Dividende

ICU Medical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent ICU Medical, Inc. (ICUI) au consensus : Achat Fort. L'objectif de cours moyen est de 150,38 €, soit un potentiel de +22.89% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 139,48 € à 174,35 €.

ICU Medical, Inc. : la thèse d'investissement en détail

ICU Medical, Inc. (ICUI) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 22.89% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -12.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 2.15%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion.

Valorisation en contexte

With a PEG ratio of 0.08, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 15.09x is meaningfully below the trailing 75.06x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 22.89% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (8.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy ICU Medical, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.